

Filed: August 26, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.

Petitioner,

v.

ASTRAZENECA AB

Patent Owner.

---

Case No. IPR2016-01316 (6,774,122)

Case No. IPR2016-01324 (7,456,160)

Case No. IPR2016-01325 (8,329,680)

Case No. IPR2016-01326 (8,466,139)<sup>1</sup>

---

**SECOND UPDATED MANDATORY NOTICE PURSUANT TO  
37 CFR §§ 42.8(a)(3) AND (b)(2)**

---

<sup>1</sup> A word-for-word identical Notice is being filed in each proceeding.

Pursuant to 37 C.F.R. §§ 42.8(a)(3) and 42.8(b)(2), Petitioner hereby identifies the following litigation in which United States Patent Nos. 6,774,122, 7,456,160, 8,329,680, and 8,466,139 are asserted by Patent Owner:

- *AstraZeneca Pharmaceuticals LP et al. v. Mylan Institutional LLC*,  
Civil Action No. 1:16-cv-00669 (D. Del.), filed August 5, 2016.

Dated: August 26, 2016

/Brandon M. White/  
Brandon M. White  
Reg. No. 52,354  
Perkins Coie LLP  
700 13th St. NW, Suite 600  
Washington, D.C. 20005  
Telephone: (202) 654-6206  
E-mail: [bmwhite@perkinscoie.com](mailto:bmwhite@perkinscoie.com)

*Attorney for Mylan Pharmaceuticals Inc.*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that the foregoing SECOND UPDATED MANDATORY NOTICE PURSUANT TO 37 CFR §§ 42.8(a)(3) AND (b)(2) was served electronically via email as follows:

Patent Owners:

Filko Prugo  
O'Melveny & Myers LLP  
fprugo@omm.com

Caitlin Hogan  
O'Melveny & Myers LLP  
chogan@omm.com

Marc Pensabene  
O'Melveny & Myers LLP  
mpensabene@omm.com

Kevin Murray  
O'Melveny & Myers LLP  
Kmurray2@omm.com

Dated: August 26, 2016

/Brandon M. White/  
Brandon M. White

*Attorney for Mylan Pharmaceuticals Inc.*